Ampio' subisidary establishes study collaboratoins with two research centers Ampio announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center and the University of Thessaly. These two leading oxidative stress research groups will utilize Luoxis' proprietary RedoxSYS oxidation-reduction potential diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion.
Ampio says Optina benefit not significant vs. placebo, Bloomberg reports Vaughan Lennox Clift, Chief Regulatory Affairs Officer of Ampio, told Bloomberg in a phone interview that Optina's benefit is not significant versus the placebo. Optina helped a group improve from baseline, Bloomberg adds. Clift also said the FDA may allow narrow sales with a post-market study.